[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"condbio:b-cell-non-hodgkin-lymphoma:ms4a1-gene":3},{"condition":4,"biomarker":5,"total":6,"trials":7},"B-Cell Non-Hodgkin Lymphoma","MS4A1 Gene",6,[8,16,23,29,36,43],{"nct_id":9,"title":10,"phases":11,"status":13,"updated_at":14,"content_modified":15},"NCT06954805","Defining ctDNA Metrics in Posttransplant Lymphoproliferative Disorder (PTLD)",[12],"Phase 2","RECRUITING","2026-08-26T02:17:52.450442Z","2026-05-05T02:43:29.355601Z",{"nct_id":17,"title":18,"phases":19,"status":13,"updated_at":21,"content_modified":22},"NCT07283679","Phase I\u002FII Trial of ONC-PluReceptor NK Cells With Epcoritamab and Tafasitamab for Patients With Recurrent or Refractory B-cell Non-Hodgkin Lymphoma",[20],"Phase 1\u002FPhase 2","2026-08-26T02:18:03.638950Z","2026-05-05T02:43:27.977643Z",{"nct_id":24,"title":25,"phases":26,"status":13,"updated_at":27,"content_modified":28},"NCT05615636","A Phase II Trial of Mosunetuzumab, Polatuzumab, Tafasitamab, and Lenalidomide in Patients With Relapsed B-cell NHL",[12],"2026-08-26T02:17:23.750999Z","2026-05-05T02:43:27.476441Z",{"nct_id":30,"title":31,"phases":32,"status":13,"updated_at":34,"content_modified":35},"NCT06209619","CC-99282 + Rituximab Early Post CART for Non-Hodgkin's Lymphoma",[33],"Phase 1","2026-08-26T02:15:10.362237Z","2026-05-05T02:43:28.853554Z",{"nct_id":37,"title":38,"phases":39,"status":40,"updated_at":41,"content_modified":42},"NCT05421663","A Study of JNJ-90014496 in Participants With B-Cell Non-Hodgkin Lymphoma",[20],"ACTIVE_NOT_RECRUITING","2026-08-03T03:30:50.548292Z","2026-05-05T02:43:29.152099Z",{"nct_id":44,"title":45,"phases":46,"status":40,"updated_at":47,"content_modified":48},"NCT05412290","Mosunetuzumab Consolidation Therapy After autoSCT in r\u002Fr Aggressive B Cell Lymphoma",[33],"2026-08-03T03:30:23.638222Z","2026-05-05T02:43:28.878051Z"]